Switching to or From Avodart (Dutasteride): Patient Reports, Clinical Evidence, and What to Expect

Why Patients Consider Switching to Dutasteride

Most patients who switch to dutasteride have already tried finasteride and found it insufficient. The pharmacology explains why this move makes sense: finasteride blocks only type II 5-alpha reductase, while dutasteride inhibits both type I and type II isoenzymes. The result is serum DHT suppression exceeding 90%, compared to roughly 70% with finasteride [1].

In the CombAT trial (N=4,844), dutasteride 0.5 mg reduced prostate volume by 25.7% at 24 months in men with BPH, outperforming tamsulosin monotherapy in preventing acute urinary retention and BPH-related surgery [2]. For men whose IPSS scores remain elevated on finasteride alone, that additional DHT suppression often translates to clinically meaningful symptom relief.

The American Urological Association (AUA) 2023 BPH guidelines state: "5-alpha reductase inhibitors should be offered to patients with LUTS associated with demonstrable prostatic enlargement" and recognize both dutasteride and finasteride as appropriate options, with the choice left to clinician judgment [3]. Patient-reported switching experiences on forums like r/Trt and Drugs.com tend to cluster around two scenarios: men with BPH who plateau on finasteride, and men using these medications off-label for androgenetic alopecia who want stronger DHT blockade.

Finasteride to Dutasteride: The Most Common Switch

The finasteride-to-dutasteride switch is the transition most frequently discussed in both clinical literature and patient communities. It is a straightforward change. Most prescribers simply discontinue finasteride and start dutasteride 0.5 mg the next day, with no taper or washout required.

Eun et al. (2010) conducted a randomized, investigator-blinded trial comparing dutasteride 0.5 mg daily to finasteride 1 mg daily in 416 Korean men with androgenetic alopecia over 24 weeks. The dutasteride group gained a mean of 109.6 hairs/cm² in the target area versus 75.6 hairs/cm² with finasteride (P<0.001) [4]. This 45% superiority in hair count is the statistic most often cited in Reddit threads (r/tressless, r/HairTransplants) when users justify their decision to switch.

Patient reports on Drugs.com reviews reflect this data, though with considerable variability. Users who switched after 12+ months on finasteride commonly describe noticing reduced shedding within 6 to 8 weeks and visible thickening by month 4 or 5. Selection bias is a real factor here: patients who switch are already a self-selected group unhappy with their current treatment, and those who post reviews skew toward strong responders or those experiencing side effects.

A recurring theme across forum reports is the psychological weight of the decision. Many users describe spending months researching before making the change. The side effect fear is real, even among those who tolerated finasteride without issues. A 2019 pharmacovigilance analysis of FDA Adverse Event Reporting System (FAERS) data found that dutasteride's reported side effect profile was broadly similar to finasteride's, with sexual dysfunction being the most common complaint in both groups [5].

Switching Away From Dutasteride: The Half-Life Problem

Leaving dutasteride is not as simple as stopping a pill. This is a point many patients underestimate. Dutasteride's terminal half-life of approximately 5 weeks means the drug persists in serum for months after the last dose [1]. By comparison, finasteride clears within 24 to 48 hours.

The Endocrine Society's clinical practice guidelines on androgen therapy note that patients discontinuing 5-alpha reductase inhibitors should be counseled that "hormonal effects may persist for weeks to months depending on the agent's half-life" [6]. For dutasteride specifically, serum DHT levels may not fully normalize for 4 to 6 months after discontinuation.

This has practical consequences in two scenarios. First, men switching from dutasteride to finasteride (a "step-down" for side effect management) sometimes report a confusing overlap period where they cannot tell which drug is responsible for their symptoms. Second, men stopping dutasteride entirely before attempting conception should plan 3 to 6 months of washout, per urological consensus. The AUA notes that 5-alpha reductase inhibitors can reduce sperm count and should be discontinued in men actively pursuing fertility [3].

Patient reports on Reddit (r/Trt, r/FinasterideSyndrome) describe this prolonged washout as frustrating. Some users report persistent side effects weeks after stopping, only to realize later that the drug was still active in their system. Clinician counseling at the point of discontinuation matters. Setting the expectation that normalization takes months, not days, reduces unnecessary anxiety.

Switching Between Dutasteride and Tamsulosin

A second common switching pattern involves moving between dutasteride and the alpha-blocker tamsulosin (Flomax), or combining them. The CombAT trial directly compared dutasteride monotherapy, tamsulosin monotherapy, and their combination in men with moderate-to-severe BPH [2].

At 4 years, combination therapy reduced the relative risk of acute urinary retention by 67.6% compared to tamsulosin alone and by 18.3% compared to dutasteride alone [2]. The AUA guidelines recommend combination therapy for men with LUTS and prostatic enlargement, particularly those with prostate volumes exceeding 30 mL [3].

In practice, the switching conversation often goes in this direction: a patient starts tamsulosin for rapid symptom relief (onset within days to 2 weeks), then either adds or transitions to dutasteride for long-term prostate volume reduction. Dr. Kevin McVary, then chair of the AUA BPH guidelines panel, stated in a 2018 guideline commentary: "Alpha-blockers provide rapid symptom relief, but 5-alpha reductase inhibitors are the only medical therapy proven to alter the natural history of BPH progression" [3].

Patients who switch from combination therapy to dutasteride alone sometimes notice a transient worsening of flow-related symptoms. The alpha-blocker withdrawal unmasks urethral smooth muscle tone that tamsulosin was relaxing. This typically resolves within 2 to 4 weeks as patients adjust, but it catches some patients off guard.

PSA Monitoring During and After Switching

Dutasteride approximately halves serum PSA values. This is a known pharmacologic effect, not a sign that prostate cancer risk has been eliminated. The REDUCE trial (N=8,231) established that dutasteride reduced overall prostate cancer detection by 22.8% over 4 years, but also showed a non-significant increase in high-grade (Gleason 8-10) tumors in the dutasteride arm [7].

The FDA label for Avodart specifies: "For interpretation of an isolated PSA value in a man treated with dutasteride for 6 months or more, the PSA value should be doubled for comparison with normal ranges in untreated men" [1]. This doubling rule applies during treatment and for months after discontinuation, given the long half-life. Dr. Peter Carroll of UCSF, writing in the Journal of Urology, emphasized that "failure to account for the PSA-lowering effect of 5-alpha reductase inhibitors can lead to delayed cancer detection" [8].

Patients switching to dutasteride from finasteride will see an additional PSA drop, since dutasteride suppresses DHT more aggressively. Patients switching off dutasteride will see PSA values gradually rise over 3 to 6 months as DHT normalizes. Both transitions require clear communication with the prescribing clinician and any other providers ordering PSA tests.

What Real-World Reviews Say About the Switching Experience

Online review aggregators and patient forums provide a window into the switching experience, though sample sizes are small and selection bias is significant. On Drugs.com, dutasteride carries an average rating of approximately 6.8 out of 10 for BPH based on user-submitted reviews, with higher scores among long-term users (2+ years) and lower scores in the first 6 months [9].

Common positive themes in switching reviews include better urinary flow within 3 months, reduced nocturia, and (for off-label hair loss users) visible hair thickening that finasteride alone did not achieve. Negative themes center on sexual side effects (reduced libido, erectile changes) and the anxiety of switching medications.

A systematic review published in the Journal of the American Academy of Dermatology analyzed patient-reported outcomes across 5-alpha reductase inhibitor studies and found that sexual side effects occurred in 3.4% to 15.8% of patients depending on the study, with no consistent difference between dutasteride and finasteride [10]. The wide range reflects differences in how sexual dysfunction was measured (spontaneous reporting vs. validated questionnaires) and the populations studied.

Reddit communities (r/tressless, r/HairLoss) are among the most active discussion spaces for dutasteride switching reports. A repeated pattern: users who switch from finasteride to dutasteride report an initial "shed" phase lasting 4 to 8 weeks, followed by regrowth. This mirrors the well-documented shedding phase seen when initiating any 5-alpha reductase inhibitor, where miniaturized hairs are pushed out by new anagen-phase growth [4]. The shedding alarms new switchers, but it is pharmacologically expected.

Timeline Expectations for Switchers

Setting realistic timelines is one of the most valuable things a clinician can do during a switch.

For BPH, the AUA guidelines note that 5-alpha reductase inhibitors require 6 to 12 months for maximal prostate volume reduction, with symptom improvement often beginning at 3 to 6 months [3]. Patients switching from finasteride to dutasteride may see incremental benefit sooner, since they already have partial DHT suppression. The CombAT data showed statistically significant separation between dutasteride and tamsulosin monotherapy by month 9 for symptom scores [2].

For off-label hair loss treatment, the Eun et al. trial measured outcomes at 24 weeks (approximately 6 months). Meaningful hair count differences between dutasteride and finasteride were already apparent at 12 weeks [4]. Patient forums corroborate this: most switchers who ultimately report satisfaction describe visible changes between months 3 and 6. Those who see nothing by month 9 are less likely to continue.

For discontinuation, expect 4 to 6 months for full DHT normalization after stopping dutasteride, compared to 2 to 4 weeks after stopping finasteride. Any side effects attributable to DHT suppression should resolve on a similar timeline, though individual variation exists.

Safety Signals and What to Watch For

The most important safety consideration during any dutasteride switch involves monitoring for mood changes, sexual function changes, and breast tissue changes (gynecomastia). A 2017 meta-analysis in the Journal of the European Academy of Dermatology and Venereology pooled data from 2,385 patients across dutasteride trials and found gynecomastia rates of 1.0% to 2.3%, generally resolving after discontinuation [11].

Patients with a history of depression should discuss this with their prescriber before switching. The FDA updated the finasteride label in 2012 to include depression as a potential adverse event, and the same pharmacologic class concern applies to dutasteride [1]. Large-scale observational data from a 2021 JAMA Dermatology study (N=3,754 finasteride users) found no statistically significant increase in depression incidence, but individual susceptibility varies [12].

Blood donation restrictions represent another practical consideration. The FDA requires a 6-month deferral after the last dose of dutasteride before donating blood, because the drug could cause birth defects if transfused to a pregnant woman [1]. This is longer than the 1-month deferral for finasteride.

Patients switching to dutasteride should have a baseline PSA drawn before starting, and follow-up PSA at 3 to 6 months to establish their new suppressed baseline. Any PSA rise during treatment (after doubling the value) warrants the same workup as a PSA rise in an untreated patient.